Please be advised that there is an error in [Table I](#tI-co16-5-120){ref-type="table"} of "The Role of HER2-targeted Therapies in Women with HER2-Overexpressing Metastatic Breast Cancer" by Dent *et al.* which appeared in *Current Oncology* Volume 16, Number 4 on page 236 in print, and page 26 online. The median [ttp]{.smallcaps} in the Slamon *et al*. trial in the column labeled "*Trastuzumab AND \[paclitaxel OR (anthracycline AND cyclophosphamide)\]"* should read 7.4 not 4.7 as originally printed. The corrected version of the table can be found below.

###### 

Efficacy results from pivotal first-line metastatic breast cancer trials

  Clinical endpoint                   Trial arms Slamon et al., 2001^18^(*n*=469)   Trial arms Marty et al., 2005 and 2006^19,20^ (*n*=186)          
  ----------------------------------- --------------------------------------------- --------------------------------------------------------- ------ ------
  Median [orr]{.smallcaps} (%)        50                                            32                                                        61     34
                                      *p*\<0.001                                    *p*=0.0002                                                       
  Median [dr]{.smallcaps} (months)    9.1                                           6.1                                                       11.7   5.7
                                      *p*\<0.001                                    *p*=0.009                                                        
  Median [ttp]{.smallcaps} (months)   7.4                                           4.6                                                       11.7   6.1
                                      *p*\<0.001                                    *p*=0.0001                                                       
  Median [os]{.smallcaps} (months)    25.1                                          20.3                                                      31.2   22.7
                                      *p*=0.046                                     *p*=0.0325[a](#tfn1-co16-5-120){ref-type="table-fn"}             

Trial survival results were updated at the 2006 San Antonio Breast Cancer Symposium. The superior survival benefit for trastuzumab plus docetaxel over docetaxel alone was maintained (31.2 months vs. 22.7 months); however, the survival difference was no longer significant (*p* = 0.0876), perhaps because most of the patients randomized to docetaxel alone (57%) subsequently crossed over to receive trastuzumab.

[orr]{.smallcaps} = objective response rate; [dr]{.smallcaps} = duration of response; [ttp]{.smallcaps} = time to progression; [os]{.smallcaps} = overall survival.
